Sun Pharma Share Price Prediction: 2025, 2026, 2027, 2030, 2040, 2050
Jump To:
Who is Sun Pharma?
With its roots stretching back to 1983, Sun Pharmaceutical Industries Ltd. has grown from a small Indian manufacturer into a global pharmaceutical powerhouse. Today, Sun Pharma is a go-to choice for retail investors and market veterans alike, thanks to its focus on innovative therapies, wide product basket, and a presence in over 100 countries. Their future-forward attitude—a balanced mix of R&D, smart acquisitions, and scale—has earned them not just impressive revenues, but also trust across continents.
Sun Pharma’s Core Numbers (2025)
| Metric | Value |
|---|---|
| Market Cap | ₹446,520 Cr |
| P/E Ratio | 42.49 |
| EPS | ₹43.45 |
| Dividend Yield | 0.73% |
| ROE / ROCE | 15.04% |
| Debt/Equity | 0.04 |
| 52W High / Low | ₹1,873.35 / ₹1,068.35 |
| Book Value Per Share | ₹265.49 |
| Promoter Holding | 54.48% |
These numbers highlight Sun Pharma’s prudent debt management, consistent profitability, and attractive position for those seeking a stable pharma stock with growth perks.
2025 Sun Pharma Monthly Share Price Targets
Let’s break down 2025 for Sun Pharma, month by month. These figures blend analyst insight with market momentum and recent company performance:
| Month | Min Target (₹) | Max Target (₹) |
|---|---|---|
| January | 1,693 | 1,902 |
| February | 1,568 | 1,789 |
| March | 1,510 | 1,795 |
| April | 1,472 | 1,808 |
| May | 1,620 | 1,957 |
| June | 1,766 | 2,044 |
| July | 1,650 | 1,748 |
| August | 1,500 | 1,850 |
| September | 1,554 | 2,011 |
| October | 1,610 | 2,147 |
| November | 1,725 | 2,314 |
| December | 1,884 | 2,381 |
For 2025, Sun Pharma’s price could swing between ₹1,366 and ₹2,381. This makes it attractive for medium-term traders watching new product launches or sector trends.
2026 Sun Pharma Monthly Share Price Targets
Sun Pharma’s big plays in biosimilars, an expanding global reach, and fresh product rollouts could drive the following 2026 trajectory:
| Month | Min Target (₹) | Max Target (₹) |
|---|---|---|
| January | 2,251 | 2,500 |
| February | 2,315 | 2,586 |
| March | 2,400 | 2,750 |
| April | 2,550 | 2,925 |
| May | 2,600 | 3,000 |
| June | 2,700 | 3,090 |
| July | 2,800 | 3,150 |
| August | 2,850 | 3,190 |
| September | 2,900 | 3,250 |
| October | 3,000 | 3,300 |
| November | 3,100 | 3,313 |
| December | 3,200 | 3,313 |
If growth and regulatory wins align, Sun Pharma could push comfortably above ₹3,000 before the year closes.
2027 Sun Pharma Monthly Share Price Targets
Looking at 2027, tailwinds from patent wins, innovation, and continuing international expansion could send Sun Pharma into new price territory:
| Month | Min Target (₹) | Max Target (₹) |
|---|---|---|
| January | 3,350 | 3,450 |
| February | 3,400 | 3,550 |
| March | 3,500 | 3,650 |
| April | 3,600 | 3,750 |
| May | 3,700 | 3,800 |
| June | 3,800 | 3,900 |
| July | 3,850 | 4,000 |
| August | 4,000 | 4,200 |
| September | 4,200 | 4,300 |
| October | 4,300 | 4,350 |
| November | 4,350 | 4,400 |
| December | 4,400 | 4,500 |
If Sun Pharma’s pipeline delivers as projected, the stock has room to grow into the ₹4,000-₹4,500s by year-end.
Long-Term View: 2030, 2040, 2050 Price Range
| Year | Min Price (₹) | Max Price (₹) |
|---|---|---|
| 2030 | 3,500 | 4,500 |
| 2040 | 7,000 | 9,500 |
| 2050 | 10,000 | 15,000 |
These numbers aren’t guarantees. They reflect steady execution, ongoing new launches, and the typical boom-bust cycles seen in pharma stocks.
Growth Path Visual
(Each bar’s length shows the max projected share price — keep in mind, these are directional, not exact.)
Analyst View: Buy or Wait?
Reasons Bulls Like Sun Pharma
- Dominance in India’s market and a robust global brand
- Well-funded, persistent R&D and specialty launches
- Competitive cost efficiency with low leverage
- Diversified segments (brand, generics, API, specialty)
Possible Risks (Bearish Views)
- Unexpected regulatory snags in the US, EU, or India
- Generic pricing pressure
- Currency swings can hit global earnings
- Heavy reliance on a few blockbusters
Bottom Line: Sun Pharma looks well placed to ride out sector volatility. That said, don’t skip your own due diligence—especially if you’re betting big on pharma!
Recent Sun Pharma Financials
| Quarter | Revenue (₹ Cr) | Net Profit (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Q2 FY24 | 12,192 | 2,375 | 9.91 |
| Q1 FY24 | 11,519 | 2,061 | 8.60 |
| Q4 FY23 | 10,844 | 1,984 | 8.28 |
| Q3 FY23 | 11,241 | 2,166 | 9.04 |
FAQs: Sun Pharma Stock
- What gives Sun Pharma its edge? A healthy mix of R&D, smart expansion, and proven execution across domestic and global markets.
- How risky is Sun Pharma compared to peers? Lower debt and a strong India/US footprint make it steadier, but pharma always carries regulatory and patent risks.
- Where can I get regular Sun Pharma Updates?
Get Sun Pharma News First: Join Our Telegram!
Want price alerts, analysis, and community support on your investing journey?
👉 Join Our Telegram Channel
Post Comment